BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 29737901)

  • 21. Comprehensive analysis of serum chromogranin A and neuron-specific enolase levels in localized and castration-resistant prostate cancer.
    Szarvas T; Csizmarik A; Fazekas T; Hüttl A; Nyirády P; Hadaschik B; Grünwald V; Püllen L; Jurányi Z; Kocsis Z; Shariat SF; Sevcenco S; Maj-Hes A; Kramer G
    BJU Int; 2021 Jan; 127(1):44-55. PubMed ID: 32314509
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Age dependence and prognostic impact of neuron specific enolase (NSE) in children with neuroblastoma.
    Berthold F; Engelhardt-Fahrner U; Schneider A; Schumacher R; Zieschang J
    In Vivo; 1991; 5(3):245-7. PubMed ID: 1893081
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Circulating neuroendocrine markers in patients with prostate carcinoma.
    Berruti A; Dogliotti L; Mosca A; Bellina M; Mari M; Torta M; Tarabuzzi R; Bollito E; Fontana D; Angeli A
    Cancer; 2000 Jun; 88(11):2590-7. PubMed ID: 10861438
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancer.
    Pujol JL; Quantin X; Jacot W; Boher JM; Grenier J; Lamy PJ
    Lung Cancer; 2003 Feb; 39(2):131-8. PubMed ID: 12581564
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Choice of tumour markers in patients with neuroendocrine tumours is dependent on the histological grade. A marker study of Chromogranin A, Neuron specific enolase, Progastrin-releasing peptide and cytokeratin fragments.
    Korse CM; Taal BG; Vincent A; van Velthuysen ML; Baas P; Buning-Kager JC; Linders TC; Bonfrer JM
    Eur J Cancer; 2012 Mar; 48(5):662-71. PubMed ID: 21945100
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of the relationship between MYCN gene and serum NSE and urinary VMA levels and neuroblastoma pathological features and prognosis.
    Zhang H; He X; Miao Q; Li L; Song J; Jiang X
    Cell Mol Biol (Noisy-le-grand); 2024 Apr; 70(4):134-139. PubMed ID: 38678619
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical significance of progastrin-releasing peptide, neuron-specific enolase, chromogranin a, and squamous cell cancer antigen in pulmonary neuroendocrine tumors.
    Tutar N; Yetkin NA; Yazıcı C; Önal Ö; Kontaş O; Keleştemur F
    Turk J Med Sci; 2019 Jun; 49(3):774-781. PubMed ID: 31091854
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum neuron-specific enolase in children with neuroblastoma. Relationship to stage and disease course.
    Zeltzer PM; Marangos PJ; Evans AE; Schneider SL
    Cancer; 1986 Mar; 57(6):1230-4. PubMed ID: 3002599
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical significance of blood chromogranin A measurement in neuroendocrine tumours.
    Seregni E; Ferrari L; Bajetta E; Martinetti A; Bombardieri E
    Ann Oncol; 2001; 12 Suppl 2():S69-72. PubMed ID: 11762355
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasma levels of chromogranin A are directly proportional to tumour burden in neuroblastoma.
    Wassberg E; Stridsberg M; Christofferson R
    J Endocrinol; 1996 Nov; 151(2):225-30. PubMed ID: 8958782
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuroendocrine tumor markers and enterochromaffin-like cell hyper/dysplasia in type 1 diabetes.
    De Block CE; Colpin G; Thielemans K; Coopmans W; Bogers JJ; Pelckmans PA; Van Marck EA; Van Hoof V; Martin M; De Leeuw IH; Bouillon R; Van Gaal LF
    Diabetes Care; 2004 Jun; 27(6):1387-93. PubMed ID: 15161793
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuroendocrine differentiation in colorectal carcinomas.
    Syversen U; Halvorsen T; Mårvik R; Waldum HL
    Eur J Gastroenterol Hepatol; 1995 Jul; 7(7):667-74. PubMed ID: 8590163
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospective Evaluation of Neuromediator Dynamics in Castration-Resistant Prostate Cancer Patients During Docetaxel.
    VON Hardenberg J; Schwartz M; Werner T; Fuxius S; Müller M; Frangenheim T; Bolenz C; Weiss C; Heinrich E
    Anticancer Res; 2017 Sep; 37(9):5117-5124. PubMed ID: 28870943
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correlation of three immunohistochemically detected markers of neuroendocrine differentiation with clinical predictors of disease progression in prostate cancer.
    Ather MH; Abbas F; Faruqui N; Israr M; Pervez S
    BMC Urol; 2008 Dec; 8():21. PubMed ID: 19115997
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Routine measurement of plasma chromogranin B has limited clinical utility in the management of patients with neuroendocrine tumours.
    Monaghan PJ; Lamarca A; Valle JW; Hubner RA; Mansoor W; Trainer PJ; Darby D
    Clin Endocrinol (Oxf); 2016 Mar; 84(3):348-52. PubMed ID: 26608723
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of neuroendocrine serum markers in the follow-up of patients with cancer of the prostate.
    Angelsen A; Syversen U; Stridsberg M; Haugen OA; Mjølnerød OK; Waldum HL
    Prostate; 1997 May; 31(2):110-7. PubMed ID: 9140124
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors.
    Bajetta E; Ferrari L; Martinetti A; Celio L; Procopio G; Artale S; Zilembo N; Di Bartolomeo M; Seregni E; Bombardieri E
    Cancer; 1999 Sep; 86(5):858-65. PubMed ID: 10463986
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum Neuroendocrine Markers Predict Therapy Outcome of Patients with Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis.
    Liu Y; Zhao S; Wang J; Zhu Z; Luo L; Li E; Tang F; Zhao Z
    Urol Int; 2019; 102(4):373-384. PubMed ID: 30517936
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The use of neuron specific enolase in the prognosis and followup of neuroblastoma in children. Results of a retrospective series of 21 patients].
    Abdennebi M; Boussen H; Harzallah L; Daldoul O; Ghanem A; Gamoudi A; Ben Slimene F; Rahal K; el May A; Ben Ayed F; Guemira F
    Tunis Med; 2000 Feb; 78(2):106-8. PubMed ID: 10894045
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Are biochemical markers of neuroendocrine tumors coreleased with insulin following local calcium stimulation in patients with insulinomas?
    Wiesli P; Uthoff H; Perren A; Pfammatter T; Zwimpfer C; Seiler H; Kindhauser R; Spinas GA; Schmid C
    Pancreas; 2011 Oct; 40(7):995-9. PubMed ID: 21705951
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.